Tag: NCX
Nicox plans to secure funding to support the clinical development of NCX 470
By Arnaud Bivès Published on 03/13/2024 at 08:40 a.m. (Boursier.com) — Nicox whose resources are focused on…
Nicox is focusing its strengths on the development of its NCX 470 product
(AOF) – Nicox announces that its resources are focused on the clinical development of its main program, NCX 470, against glaucoma. The biotech specializing in ophthalmology is counting on obtaining…
Nicox: License agreement with Kowa for the development and marketing of the NCX 470 in Japan
By Hector Chaunu Published on 02/08/2024 at 08:09 a.m. (Boursier.com) — Nicox SA, an international company specializing in…
Nicox: Potential annual worldwide net sales of the NCX 470 estimated at more than $300 million
(Boursier.com) — Nicox SA Announces Market Research in the United States to Assess the Commercial Potential of NCX 470, a Nitric Oxide (NO)-Donating Bimatoprost, in Development for the Reduction of…
Nicox up sharply after study on NCX 470 trade outlook – 7/10/2023 at 10:03 am
(AOF) – Nicox (+ 14.69% to 0.53 euro) posted one of the strongest increases in the SRD market after having made public a market study according to which its product…
Nicox: Presentation at the World Glaucoma Congress of Data on NCX 470 from the Adaptive Dose Selection Step of the Phase 3 Mont Blanc Study and Analysis of Patient Subgroups Showing Superiority of NCX 470 compared to latanoprost – 07/03/2023 at 07:41
Nicox announced that additional data on NCX 470 was presented at the 10th World Glaucoma Congress (WGC) held from June 28 to July 1, 2023 in Rome, Italy. NCX 470…
Nicox: Development and partnership plans for NCX 470 in glaucoma – 07/11/2022 at 07:37
Nicox SA, an international company specializing in ophthalmology, today announces development and partnership plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 clinical…
Nicox: NCX 470 has achieved the primary objective of the Mont Blanc study (glaucoma) – 31/10/2022 at 10:07
(AOF) – Nicox SA, an international specialty ophthalmology company, today announces that NCX 470 0.1% administered once daily has achieved the primary endpoint of non-inferiority in the reduction of intraocular…
Nicox: Results of the Dolomites Phase 2 clinical study of NCX 470 published in the Journal of Glaucoma – 04/11/2022 at 07:40
Nicox today announces the publication of the results of the Phase 2 Dolomites clinical study of NCX 470 in patients with open-angle glaucoma or ocular hypertension in the Journal of…